Novel Therapeutic Approaches for the Management of Diebetic Foot Ulceration

描述(申请人提供)：糖尿病足溃疡(DFU)和相关的损害愈合，是一个严重损害糖尿病患者的生活质量的主要问题，导致住院时间延长，仅在美国每年就有超过70,000例下肢截肢。然而，对于糖尿病创面愈合受损的分子生理机制的临床基础研究很少，这阻碍了有效治疗方法的发展。目前应用的主要目标是在生物工程、基础研究和转化研究的研究人员之间建立合作，最终将导致新的生物材料的开发，从而改善DFU的愈合。为此，将有来自怀斯研究所和哈佛大学工程与应用科学学院的两名研究人员(Mooney博士和Shih博士)，他们在开发新的生物材料方面具有丰富的经验，以及来自贝丝以色列女执事医疗中心的两名研究人员(Veves博士和Logerfo博士)，他们在糖尿病伤口愈合方面具有丰富的研究经验。Mooney博士和Shih博士将构建能够释放在PIS实验室中研究表明可以改善伤口愈合的物质的新生物材料，如神经肽、PTP1B抑制剂、生长因子和内皮祖细胞，并将在Veves博士和Logerfo实验室开发的动物模型上进行测试。这一合作有可能创建一支独特、功能强大和协同的研究团队，其专业知识涵盖新生物材料开发所需的所有领域，并将专门专注于改善糖尿病伤口的愈合。我们坚信并希望，这种合作将导致开发治疗DFU的新治疗方法，并将在未来五到十年内投入临床使用。 公共卫生相关性：目前的应用旨在为一个主要的临床项目开发新的治疗方法，即糖尿病足溃疡的管理。该项目的成功完成可能会对目前的临床实践产生重大影响。

DESCRIPTION (provided by applicant): Diabetic foot ulceration (DFU) and associated impairedhealing, is a major problem that significantly impairs the quality of life of diabetic patients, leading to prolonged hospitalization and resulting to more than 70,000 lower extremity amputations per year in the USA alone. However, there has been very little clinically driven basic research into the molecular mechanisms of the pathophysiology of impaired wound healing in diabetes, hampering the development of effective treatments. The main aim of the current application is to establish collaboration between investigators from bioengineering, basic and translational research that will eventually lead to the development of new biomaterials that will improve DFU healing. To this end, it will involve two investigators from the Wyss Institute and Harvard School of Engineering and Applied Sciences (Drs. Mooney and Shih), with extensive experience on developing new biomaterials and two investigators from the Beth Israel Deaconess Medical Center (Drs. Veves and LoGerfo) with extensive research experience in diabetic wound healing. The new biomaterials that can release substances that studies in the PIs laboratory have shown to improve wound healing, such as neuropeptides, PTP1B inhibitors, growth factors and endothelial progenitor cells, will be constructed will be constructed by the Drs. Mooney and Shih, and will be tested on animal models that have been developed by Drs. Veves' and LoGerfo's laboratory. This collaboratoryoration has the potential to create a unique, highly functional and synergistic investigative team with expertise that cover the whole range of fields that is required for the development of new biomaterials and will exclusively focus in improving diabetic- wound healing. It is our strong belief and hope that this collaboration will lead to the development of new therapeutic approaches for the treatment of DFU that will be clinically available over the next five to ten years. PUBLIC HEALTH RELEVANCE: The current application aims to develop new therapeutic approaches for a major clinical program, namely the management of diabetic foot ulcerations. Successful completion of this project may have a significant impact on the current clinical practice.